Cognition Therapeutics Inc (CGTX) is not a strong buy at the moment for a beginner investor with a long-term strategy. The technical indicators are mixed, with bearish moving averages and no clear trading signals. The financial performance shows significant declines in net income and EPS, and there are no recent positive catalysts or news to support a bullish outlook. Given the lack of strong signals and the investor's preference for long-term growth, it is better to hold off on investing in this stock for now.

Technical Analysis

The MACD is positive and expanding, indicating potential bullish momentum. However, the RSI is neutral at 65.64, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point (1.095), with resistance levels at 1.164 and 1.206, and support levels at 1.026 and 0.984. Overall, the technical outlook is mixed.

Positive Catalysts

NULL identified. No recent news or significant trading trends from hedge funds or insiders.

Neutral/Negative Catalysts

Declining financial performance with net income down -50.39% YoY and EPS down -76.00% YoY. No recent news or positive sentiment to drive the stock higher.

Financial Performance

In Q3 2025, revenue remained at 0 with no growth. Net income dropped significantly to -$4.93M (-50.39% YoY), and EPS declined to -0.06 (-76.00% YoY). Gross margin remained at 0 with no improvement.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

2 Analyst Rating

Wall Street analysts forecast CGTX stock price to rise

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 1.090

Low

Averages

High

Current: 1.090

Low

Averages

High

B. Riley

Buy

maintain

$2 -> $3

AI Analysis

2025-11-21

Reason

B. Riley

Price Target

$2 -> $3

AI Analysis

2025-11-21

maintain

Buy

Reason

B. Riley raised the firm's price target on Cognition Therapeutics to $3 from $2 and keeps a Buy rating on the shares. Cognition's Phase 2 START trial for early Alzheimer's has fully enrolled 540 patients, reinforcing momentum from prior positive Phase 2b results and rising investigator interest in oral zervimesine, the analyst tells investors in a research note. With an 18-month primary endpoint and allowance for combination therapy, the trial design offers meaningful de-risking ahead of a mid-to-late 2027 readout, the firm adds.

H.C. Wainwright

Raghuram Selvaraju

Buy

downgrade

$5 -> $3

2025-05-27

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$5 -> $3

2025-05-27

downgrade

Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Cognition Therapeutics to $3 from $5 and keeps a Buy rating on the shares. The firm cites the anticipated equity dilution later this year to extend the company's operational runway for the target cut. Zervimesine appears applicable across multiple fronts, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CGTX

Unlock Now

CGTX Should I Buy

CGTX Should I Buy

Should You Buy Cognition Therapeutics Inc (CGTX) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch